TSToshihiro Saito

Toshihiro Saito

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Toshihiro Saito has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Age on Treatment Patterns and Outcomes in Patients With Non‐Metastatic Castration‐Resistant Prostate Cancer

    by Hiroki Hagimoto, Shinichi Sakamoto, Kodai Sato, Kazuyoshi Nakamura, Hiroki Kito, Satoshi Fukasawa, Daichi Hino, Yusuke Shiraishi, Kohei Hashimoto, Yuto Matsushita, et al.

    Objectives: To evaluate the impact of age on treatment patterns and outcomes in patients with non‐metastatic castration‐resistant prostate cancer (nmCRPC). Methods: We conducted a retrospective multicenter analysis of 428 patients with nmCRPC from 25 tertiary centers (2002–2022). Patients were divided into two age groups: < 80 and ≥ 80 years. The outcomes included cancer‐specific survival (CSS), overall survival (OS), and progression‐free survival (PFS). Results: Among 428 patients (median follow‐up, 32.5 months), performance status (PS) 0 was more frequent in < 80 vs. ≥ 80 years (78% vs. 58%, p < 0.001). Use of first‐line androgen receptor signaling inhibitors (ARSIs) was similar (58% vs. 59%, p = 0.83) among all, whereas any‐line docetaxel use was less common in patients aged ≥ 80 years (33% vs. 9% for < 80 vs. ≥ 80, p < 0.001). Five‐year CSS was 76.5% vs. 63.7% ( p = 0.002) and five‐year OS 73.8% vs. 59.9% ( p = 0.006) for < 80 vs. ≥ 80 years, respectively. Time‐to‐treatment failure was shorter in patients aged ≥ 80 years ( p = 0.04). Conclusion: Maintaining PS and managing ARSI‐related adverse events are essential in older patients with nmCRPC and may preserve their eligibility for chemotherapy and improve their prognosis.

  • Efficacy of fracture stem in reverse shoulder arthroplasty for 3- or 4-part proximal humerus fractures

    by Hideyuki Sasanuma, Yuki Iijima, Tomohiro Saito, Akihiro Saitsu, Toshihiro Saito, Tomohiro Matsumura, Katsushi Takeshita


  • Efficacy of combined androgen blockade therapy in patients with metastatic hormone‐sensitive prostate cancer stratified by tumor burden

    by Yoshiyuki Nagumo, Mizuki Onozawa, Takahiro Kojima, Naoki Terada, Masaki Shiota, Koji Mitsuzuka, Hiroaki Yasumoto, Hiroaki Matsumoto, Hideki Enokida, Takayuki Sugiyama, et al.

    Objective: To determine the effect of combined androgen blockade with a first‐generation anti‐androgen on the prognoses of metastatic hormone‐sensitive prostate cancer patients stratified by tumor burden.Methods: We retrospectively analyzed the cases of metastatic hormone‐sensitive prostate cancer patients who were treated with androgen deprivation therapy in 2008–2017 at 30 institutions in Japan. To compare the overall survival and progression‐free survival rates of the patients treated with castration monotherapy and combined androgen blockade, we carried out a Cox proportional hazards regression analysis using both inverse probability of treatment weighting and instrumental variables methods. High‐burden disease was defined as the presence of four or more bone metastases and/or visceral metastasis.Results: Of 2048 patients, 702 (34.3%) and 1346 (65.7%) patients were classified as the low‐ and high‐burden groups, respectively. In each group, >80% of the patients were treated with combined androgen blockade. Although there was no significant between‐group difference in the overall survival according to the androgen deprivation therapy method, in the high‐burden group the progression‐free survival of the combined androgen blockade‐treated patients was significantly better than that of patients treated with castration monotherapy: inverse probability of treatment weighting method, hazard ratio 0.49, 95% confidence interval 0.34–0.71; instrumental variables method, hazard ratio 0.80, 95% confidence interval 0.60–0.98.Conclusion: In the high‐burden group, combined androgen blockade with a first‐generation anti‐androgen resulted in superior progression‐free survival compared with castration monotherapy. For well‐selected metastatic hormone‐sensitive prostate cancer patients, the use of combined androgen blockade might still have some suitable scenarios.


  • Subsequent Activation of Mitogen-Activated Protein Kinase after Adhesion of Transitional Cell Cancer Cells to Fibronectin

    by Toshihiro Saito, Yoshihiko Tomita, Takashi Kawasaki, Vladimir Bilim, Kota Takahashi

    Introduction: In the process of tumor invasion and metastasis, interactions between tumor cells and extracellular matrix play a crucial role. Recently, it was shown that fibronectin binding to fibronectin receptor promotes mitogen-activated protein kinase (MAPK) activation after tyrosine phosphorylation of focal adhesion kinase (FAK). We investigated these signal transduction events in transitional cell cancer (TCC) cells. Materials and Methods: (1) The adhesion of T24 cells, a fibronectin-receptor-positive TCC cell line, to fibronectin was investigated; (2) the MAPK activation after fibronectin stimulation in bladder cancer cell lines was examined by Western blotting using an antiactive MAPK antibody, and (3) FAK, Sos, and Grb-2 were also examined by Western blot analysis. Results and Conclusions: T24 cells adhered to fibronectin-coated dishes more quickly than to the noncoated dishes. Fibronectin stimulation induced activation of MAPK in T24, SCaBER, and HT1376 cells. However, activated MAPK was not detected in RT4 cells which do not express α5β1 integrin (major fibronectin receptor) after fibronectin stimulation. T24, SCaBER, and HT1376 expressed FAK and Sos. RT4 showed little FAK and Sos expression. Grb-2 was expressed in all cell lines. Adhesion of fibronectin-receptor-positive TCC cells to fibronectin activates the MAPK cascade, possibly resulting in activation of tumor cells.